Email this article Blockers of angiotensin receptors: a novel approach to treatment of secondary pulmonary hypertension
- Authors: Butorov IV1, Verbitsky ОN1, Butorov SI1
-
Affiliations:
- Issue: Vol 79, No 6 (2004)
- Pages: 84-87
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/29861
- ID: 29861
Cite item
Full Text
Abstract
Aim. To evaluate efficacy of losartan, a blocker of angiotensin receptors, in combined treatment of secondary pulmonary hypertension (SPH) in patients with chronic obstructive bronchitis (COB). Material and methods. Losartan effects on hemodynamics, blood gases and clinical course of the disease were studied in 29patients with COB and SPH (mean age 52 ± 1.7years). A control group consisted of 15 patients (mean age 51 ± 1.5 years) treated with cardiac glycosides and diuretic drugs. Aland B-mode Doppler echocardiography registered hemodynamic parameters. 24-h monitoring of AP and ECG were made by standard methods. Blood gases and venous rheology were examined. Results. Losartan administration in COB patients with SPH improved hemodynamics. Stroke index rose from 36.3 ± 2.1 to 45.8 ± 2.1 ml/m1 (by 26.2%, p < 0.01) in SPH functional class III, from
26.3 ± 1.9 to 32.7 ± 2.1 ml/m2 (by 24.3%, p < 0.01) in functional class IV. Cardiac index rose by 22.2 and 21.1%, respectively. Pulmonary hemodynamics improved too: systolic pressure in pulmonary artery fell by 25.7% in functional class HI, by 18.6% in functional class IV. Losartan normalized a 24-h AP profile, reduced the number of painless myocardial ischemia.
Conclusion. Use of losartan in combined therapy of patients with COB and SPH improves clinical status of the patients, corrects basic cardiohemodynamic parameters, has a positive effect on AP profiles without negative impact on blood gas composition and rheology.
26.3 ± 1.9 to 32.7 ± 2.1 ml/m2 (by 24.3%, p < 0.01) in functional class IV. Cardiac index rose by 22.2 and 21.1%, respectively. Pulmonary hemodynamics improved too: systolic pressure in pulmonary artery fell by 25.7% in functional class HI, by 18.6% in functional class IV. Losartan normalized a 24-h AP profile, reduced the number of painless myocardial ischemia.
Conclusion. Use of losartan in combined therapy of patients with COB and SPH improves clinical status of the patients, corrects basic cardiohemodynamic parameters, has a positive effect on AP profiles without negative impact on blood gas composition and rheology.
References
- Ольбинская Л. И,, Игнатенко С. Б. Современные представления о патогенезе и лечении хронической сердечной недостаточности. Клин. мед. 2000; 8: 22-27.
- Присветова Е. Л. Роль вазоактивных эндотелиальных факторов в развитии артериальной гипертензии. Гедеон Рихтер в СНГ. 2001; 4: 13-15.
- Визир В. А., Березин А. Е. Влияние длительного применения эналаприла, лозартана и их комбинации на качество жизни больных с застойной сердечной недостаточностью. Тер. арх. 2002; 1: 52-55.
- Бойцов С. А. Хроническая недостаточность кровообращения. Современные аспекты лечения. Гедеон Рихтер в СНГ 2000; 1: 24-27.
- Opie L. H. Angiotensin-converting enzyme inhibitors: the advance continuce. 3-rd ed.; 1999.
- Pitt В., Poole-Wilson P., Segal R. et al. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartran Heart Failure Survival Study - ELITE. J. Cardiac Failure 1999; 5(2): 146-154.
- Hedher Т., Himmelmann A. The efficacy and tolerance of one two daily doses of cprosartan in essential hypertension. J. Hypertens. 1999; 17: 129-136.
- Нестеров Ю. И., Тепляков А. Т., Споева В. И. Эффективность и переносимость ингибиторов АПФ инворила и блокатора AT, - рецепторов ангиотензина II диована у больных артериальной гипертонией I-И стадии. Клин. мед. 2002; 8: 46-49.
- Минушкина Л. О., Сидоренко Б. А., Затейщиков Д. А., Преображенский Д. В. Применение блокатора AT, - ангиотензиновых рецепторов валсартана для лечения гипертонической болезни. Кардиология 1999; 2: 28-31.
Supplementary files
